Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 420K | 382K | 1K | 0 | 0 |
| Gross Profit | -556K | -1M | -5K | -6K | -7K |
| Operating Income | -1M | -1M | -474K | -976K | -668K |
| EBITDA | -1M | -1M | -8M | -1M | -1M |
| Net Income | -1M | -1M | -8M | -1M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0006
+100.00% today
Window Change
-98.85%
Window
May 29, 2026 → Jun 15, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 12 bars · May 29, 2026 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pineapple, Inc. (PNPL) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 98.8% across the available one-year price window (May 29, 2026 → Jun 15, 2026). Baseline metrics include revenue growth of +10.0%, EPS growth of +5.9%, a dividend yield of 0.0%. What stands out right now is revenue +10.0%, EPS +5.9%, free cash flow -235.1% with operating margin -448.0% and ROIC -10.1%. Valuation already assumes a fairly strong business story at price/sales 27.8. Stock Foundry combines PNPL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PNPL
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PNPL Max Drawdown
-98.85%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PNPL and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$1.1M
-4.0% YoY
Free Cash Flow
-$543.6K
-923.3% YoY
Revenue Growth
+10.0%
EPS Growth
+5.9%
Gross Margin
323.2%
Net Margin
-267.2%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 420K | 382K | 1K | 0 | 0 |
| Gross Profit | -556K | -1M | -5K | -6K | -7K |
| Operating Income | -1M | -1M | -474K | -976K | -668K |
| EBITDA | -1M | -1M | -8M | -1M | -1M |
| Net Income | -1M | -1M | -8M | -1M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | -15 | 30 | 0 | 0 | 0 |
| Total Assets | 9M | 8M | 2K | 9M | 10M |
| Total Liabilities | 12M | 11M | 1M | 3M | 3M |
| Shareholder Equity | -3M | -3M | -1M | 6M | 7M |
| Total Debt | 8M | 8M | 220K | 1M | 1M |
| Net Debt | 8M | 8M | 220K | 1M | 1M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
544K
-923.3% YoY
Capital Expenditures
0
-100.0% YoY
Free Cash Flow
544K
-923.3% YoY
Key ratios
Gross Margin
323.2%
Operating Margin
-448.0%
Net Margin
-267.2%
ROE
9.5%
Debt / Equity
-2.58x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.